Site of prostate cancer metastasis and length of patient survival

There has long been information suggesting that exactly where prostate cancer metastasizes to (outside of the prostate itself) is really important to how long a patient might reasonably expect to survive once metastasis is evident. This is why patients with higher-risk disease get both a bone scan and a CT scan at diagnosis. … READS MORE –

Survival times among men with biochemically recurrent prostate cancer

It would hardly come as a shock to most experienced prostate cancer advocates and patients to learn that there is an association between survival time and the aggressiveness of a patient’s cancer at the time of diagnosis if that cancer progresses. … READ MORE …

A long way from actual clinical applicability, but interesting anyway …

There was an intriguing paper in the November 2013 issue of the journal Prostate suggesting that intermittent dosing with testosterone in between doses of androgen deprivation therapies may actually help men in the early stages of castration resistance to respond better to treatment over time. … READ MORE …

Delayed onset of castration resistance with serum T-based LHRH agonist regimens

A new paper just published online in Urology suggests that intermittent and testosterone (T)-based LHRH regimens are less likely to be associated with early onset of castration resistance than traditional, continuous, calender-based regimens. … READ MORE …